Publisher： Adis International
ISSN： 1173-8324
Source： Inpharma, Vol.1, Iss.1303, 2001-01, pp. : 4-4
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
Surpassing the success of imatinib mesylate in CML
Inpharma, Vol. 1, Iss. 1385, 2003-01 ,pp. :
Access to resources
Recommend
Imatinib mesylate confers large QOL benefit in CML
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 419, 2003-01 ,pp. :
First-line imatinib mesylate worth it in CML
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 403, 2003-01 ,pp. :
First-line imatinib mesylate worth it in CML
Inpharma, Vol. 1, Iss. 1378, 2003-01 ,pp. :
Imatinib mesylate: best first-line pharmacotherapy for CML
Inpharma, Vol. 1, Iss. 1379, 2003-01 ,pp. :